PEDIATRIX MEDICAL GROUP INC (MD) Stock News
NYSE:MD - New York Stock Exchange, Inc. - US58502B1061 - Common Stock - Currency: USD
MD Latest News, Press Relases and Analysis
Wall Street Analysts See a 26.4% Upside in Pediatrix Medical Group (MD): Can the Stock Really Move This High?
The mean of analysts' price targets for Pediatrix Medical Group (MD) points to a 26.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Investors Should Consider Retaining Danaher Stock Now
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
MD vs. HQY: Which Stock Is the Better Value Option?
MD vs. HQY: Which Stock Is the Better Value Option?
Mentions: HQY
MD Q1 Earnings Call: Cost Discipline, Portfolio Restructuring Drive Outperformance Amid Industry Uncertainty
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 7.4% year on year to $458.4 million. Its non-GAAP profit of $0.33 per share was 38.3% above analysts’ consensus estimates.
3 Value Stocks with Questionable Fundamentals
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
MD vs. HQY: Which Stock Should Value Investors Buy Now?
MD vs. HQY: Which Stock Is the Better Value Option?
Mentions: HQY
Can Lower Expenses Save Pediatrix Medical's Q1 Earnings?
MD's first-quarter results are likely to reflect declining hospital contract administrative fees.
Pediatrix Medical Group (MD) Shows Fast-paced Momentum But Is Still a Bargain Stock
Pediatrix Medical Group (MD) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Pediatrix Medical's Q1 Earnings Beat Estimates on Declining Costs
MD anticipates adjusted EBITDA to be between $220 million and $240 million in 2025.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Mentions: COR
MD or HQY: Which Is the Better Value Stock Right Now?
MD vs. HQY: Which Stock Is the Better Value Option?
Mentions: HQY
Pediatrix Medical Group (MD) Q1 Earnings and Revenues Surpass Estimates
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 32% and 0.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: NTRA
Pediatrix Medical Group Reports First Quarter Results
Boost Your Portfolio With These 5 Low Price-to-Book Stocks
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, MD, PFE, STNE and SAN are some such stocks.
Here's Why Pediatrix Medical Group (MD) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pediatrix Medical Group 2025 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 6, 2025
3 Medical Services Industry Stocks to Buy as AI Fuels Growth
The Zacks Medical - Services industry is undergoing a transformation on massive artificial intelligence adoption. COR, DOCS and MD are set to gain the most. Healthcare staffing shortages are leading to an increase in labor wages.
3 Reasons MD is Risky and 1 Stock to Buy Instead
Pediatrix Medical Group has been on fire lately. In the past six months alone, the company’s stock price has rocketed 51.5%, reaching $16 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
